MedPath

EASE: The Materna Prep Pivotal Study

Not Applicable
Recruiting
Conditions
Vaginal Delivery
Pelvic Organ Prolapse
Interventions
Device: Materna Prep Device
Other: Standard of Care (SOC)
Registration Number
NCT03973281
Lead Sponsor
Materna Medical
Brief Summary

This study is designed to evaluate the safety and effectiveness of the Materna Prep Device in reducing pelvic muscle injuries during vaginal delivery.

Subjects are randomized to Materna Prep Device or Standard of Care without use of the Materna Prep Device

Intervention with the Materna Prep Device is expected to be a one-time use of approximately 30-90 minutes during the 1st stage of labor.

Subject participation in the study is targeted to be 12 months from the time of the use of the device during delivery.

Detailed Description

Vaginal delivery is a major risk factor for pelvic floor dysfunction. Clinical aspects of pelvic floor dysfunction include pelvic organ prolapse, sexual dysfunction, and fecal and urinary incontinence. Trauma to the pelvic structures occurs as the fetal head passes through the vaginal canal, especially with acute distension at the time of crowning - the exiting of the fetal head.

The Materna Prep Device is a single-use, semi-automated dilator used during the first phase of labor in order to prepare the vaginal canal for vaginal delivery. By slowly pre-stretching the vagina and surrounding pelvic tissues during labor, the device is essentially dictating the strain rate of the tissue during labor. In previous feasibility studies, the elastic recovery of the tissue has been shown to be on the order of several hours, allowing the benefits of pre-stretching the vagina and surrounding pelvic tissues to last throughout labor. The device is intended to be removed prior to the initiation of the second stage of labor, for delivery to occur unobstructed.

The target patient population for this study is nulliparous women entering the first phase of labor and scheduled for vaginal delivery with an epidural.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
450
Inclusion Criteria

Criteria for inclusion

  1. Subject is scheduled for vaginal birth.
  2. Subject is gestating a single fetus.
  3. Subject is nulliparous, or had a previous pregnancy terminated within 24 weeks gestation.
  4. Subject is able and willing to comply with the protocol required follow-up visits.
  5. Subject is able and willing to provide written informed consent prior to enrollment.
  6. In the opinion of the Investigator, the subject has sufficient mental capacity to understand the informed consent form (ICF), comply with the protocol requirements, and provide clinically relevant and reliable feedback regarding their experience with the device.
  7. Subject receives epidural anesthesia during labor prior to enrollment.
  8. Subject is 18 years of age or older at time of consent.
Exclusion Criteria

Criteria for exclusion

  1. Subject has high likelihood of less than 1 hour of potential device dilation time after she arrives at the hospital.
  2. Subject is planning or requires a Caesarean-section prior to randomization.
  3. Subject begins labor with less than 36 weeks gestation.
  4. Subject has a neurological disorder that could cause pelvic floor dysfunction, such as multiple sclerosis or spinal cord injury.
  5. Subject has a collagen-associated disorder that affects tissue elasticity, such as scleroderma or Ehlers-Danlos syndrome.
  6. Subject has a localized (genital tract) or systemic infection.
  7. Subject has a medical history which could lead to pelvic floor dysfunction, such as prior pelvic fractures, pelvic soft tissue injuries, or vaginal surgery.
  8. Subject has any general health condition or systemic disease that may represent, in the opinion of the Investigator, a potential increased risk associated with device use or pregnancy.
  9. Subject has placenta previa or vasa previa.
  10. Subject has known significant chromosomal or structural fetal anomalies.
  11. Subject has a category 2 and/or 3 fetal tracing that is unresolved.
  12. Subject is observed to have friable, denuded, or markedly edematous vaginal tissue during the course of labor.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Materna Prep DeviceMaterna Prep DeviceMaterna Prep Device
Standard of Care (SOC)Standard of Care (SOC)Standard of Care (SOC)
Primary Outcome Measures
NameTimeMethod
The occurrence of pelvic muscle injury, defined as complete detachment of the levator ani muscle diagnosed via ultrasound imaging12-month Follow-up

Use transperineal ultrasound to identify levator ani muscle detachment

Secondary Outcome Measures
NameTimeMethod
The occurrence of pelvic muscle injury, defined as complete or partial detachment of the levator ani muscle diagnosed via ultrasound imaging12-Month Follow-up

Use transperineal ultrasound to identify levator ani muscle detachments

Length of 2nd Stage LaborIntra-Procedure

Compare the length of the second stage of labor, defined as the time from the cervix being dilated to 10 cm to the complete delivery of the baby between study groups.

Perineal LacerationsIntra-Procedure

Compare the rate of perineal lacerations determined by visual insepction post-delivery between study groups

C-SectionsIntra-Procedure

Compare the rate of C-Section due to arrest of labot in the second stage

Qualitative pelvic health feedback3-Month and 12-month Follow-up

Compare qualitative pelvic health feedback assessed by PFID-20 (Utilizing a 5 point scale with 0=not present to 4=quite a bit) questionnaires from subjects between study groups.

Levator Hiatal Area3-month and 12-month Follow-up

Compare the levator hiatal area (cm2 - measurement between pelvic muscle and pelvic bone)

Obstetric anal sphincter injury - OASI3-month follow-up

Compare the rate of tearing of the muscles of the anal sphincter on ultrasound between study groups.

Qualitative pain3-Month and12-month Follow-up

Compare qualitative pain assessed by VAS (0-10, with 0 being No pain and 10 being severe pain) from subjects between study groups

User SatifactionIntra-Procedure

Satisfaction assessed by a clinician satisfaction questionnaire after device use.

Types of Perineal LacerationsIntra-Procedure

Compare rate of the TYPES of perineal lacerations between study groups.

First Push to DeliveryIntra-Procedure

Compare the mean time form first push to delivery between study groups.

Operative DeliveryIntra-Procedure

Compare the rate of instrument use in vaginal deliveries between study gorups

Infant APGAR scoresIntra-Procedure

Compare infant APGAR scores between study groups. A score of 7-10 after 5 minutes is reassuring, a score of 4-6 after minutes is moderately abnormal and a score of 0-3 is concerning.

Reasons for C-SectionsIntra-Procedure

Compare incidence of the REASONS for C-Sections between study groups

Trial Locations

Locations (15)

Mayo Clinic

🇺🇸

Rochester, Minnesota, United States

Hospital of the University of Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

Lewis Katz School of Medicine at Temple

🇺🇸

Philadelphia, Pennsylvania, United States

Baylor College of Medicine

🇺🇸

Houston, Texas, United States

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

Oregon Health and Science University

🇺🇸

Portland, Oregon, United States

Christiana Care - Center for Women's & Children's Health

🇺🇸

Newark, Delaware, United States

University of California Los Angeles

🇺🇸

Los Angeles, California, United States

El Camino Hospital

🇺🇸

Mountain View, California, United States

The Cooper Health System

🇺🇸

Camden, New Jersey, United States

Rutgers Robert Wood Johnson University Hospital

🇺🇸

New Brunswick, New Jersey, United States

Rutgers New Jersey Medical School

🇺🇸

Newark, New Jersey, United States

Columbia University Irving Medical Center

🇺🇸

New York, New York, United States

The Metro Health System

🇺🇸

Cleveland, Ohio, United States

The Ohio State University Wexner Medical Center

🇺🇸

Columbus, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath